• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

建立亚洲肾功能不全儿童环孢素的生理药代动力学模型。

Development of a physiologically-based pharmacokinetic model for cyclosporine in Asian children with renal impairment.

作者信息

Yoon Sumin, Yi Sojeong, Rhee Su-Jin, Lee Hyun A, Kim Yun, Yu Kyung-Sang, Chung Jae-Yong

机构信息

Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul 03080, Republic of Korea.

Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam 13620, Republic of Korea.

出版信息

Transl Clin Pharmacol. 2019 Sep;27(3):107-114. doi: 10.12793/tcp.2019.27.3.107. Epub 2019 Sep 30.

DOI:10.12793/tcp.2019.27.3.107
PMID:32055591
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6989237/
Abstract

This study aimed to assess the pharmacokinetics of cyclosporine A (CsA) in Asian children with renal impairment (RI) by developing a physiologically-based pharmacokinetic (PBPK) model with Simcyp Simulator. The PBPK model of Asian children with RI was developed by modifying the physiological parameters of the built-in population libraries in Simcyp Simulator. The ratio of healthy and RI populations was obtained for each parameter showing a difference between the populations. Each ratio was multiplied by the corresponding parameter in healthy Asian children. The model verification was performed with published data of Korean children with kidney disease given multiple CsA administrations. Simulations were performed with different combinations of ethnicity, age, and renal function to identify the net impact of each factor. The simulated results suggested that the effect of RI was higher in children than adults for both Caucasian and Asian. In conclusion, the constructed model adequately characterized CsA pharmacokinetics in Korean children with RI. Simulations with populations categorized by ethnicity, age, and renal function enabled to assess the net impact of each factor on specific populations.

摘要

本研究旨在通过使用Simcyp模拟器开发基于生理的药代动力学(PBPK)模型,评估环孢素A(CsA)在亚洲肾功能损害(RI)儿童中的药代动力学。通过修改Simcyp模拟器中内置人群库的生理参数,建立了亚洲RI儿童的PBPK模型。获得了每个在健康人群和RI人群之间存在差异的参数的比值。将每个比值乘以健康亚洲儿童的相应参数。利用韩国肾病儿童多次给予CsA的已发表数据进行模型验证。采用不同的种族、年龄和肾功能组合进行模拟,以确定各因素的综合影响。模拟结果表明,无论是白种人还是亚洲人,儿童RI的影响都高于成人。总之,所构建的模型充分表征了韩国RI儿童中CsA的药代动力学。按种族、年龄和肾功能对人群进行模拟能够评估各因素对特定人群的综合影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/534b/6989237/7d51b535baa4/tcp-27-107-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/534b/6989237/3b4fb7430868/tcp-27-107-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/534b/6989237/25a57e75b652/tcp-27-107-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/534b/6989237/7d51b535baa4/tcp-27-107-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/534b/6989237/3b4fb7430868/tcp-27-107-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/534b/6989237/25a57e75b652/tcp-27-107-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/534b/6989237/7d51b535baa4/tcp-27-107-g003.jpg

相似文献

1
Development of a physiologically-based pharmacokinetic model for cyclosporine in Asian children with renal impairment.建立亚洲肾功能不全儿童环孢素的生理药代动力学模型。
Transl Clin Pharmacol. 2019 Sep;27(3):107-114. doi: 10.12793/tcp.2019.27.3.107. Epub 2019 Sep 30.
2
Physiologically-based pharmacokinetic model for clozapine in Korean patients with schizophrenia.韩国精神分裂症患者中氯氮平的基于生理的药代动力学模型。
Transl Clin Pharmacol. 2021 Mar;29(1):33-44. doi: 10.12793/tcp.2021.29.e3. Epub 2021 Mar 10.
3
Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations.基于生理的药代动力学建模及对肾功能/肝功能受损的年轻人和老年人群中二甲双胍药代动力学的预测
Eur J Drug Metab Pharmacokinet. 2017 Dec;42(6):973-980. doi: 10.1007/s13318-017-0418-x.
4
Development of Physiologically Based Pharmacokinetic Model for Pregabalin to Predict the Pharmacokinetics in Pediatric Patients with Renal Impairment and Adjust Dosage Regimens: PBPK Model of Pregabalin in Pediatric Patients with Renal Impairment.用于预测肾功能损害儿科患者体内药代动力学和调整剂量方案的普瑞巴林生理药代动力学模型的开发:肾功能损害儿科患者普瑞巴林的 PBPK 模型。
J Pharm Sci. 2022 Feb;111(2):542-551. doi: 10.1016/j.xphs.2021.10.026. Epub 2021 Oct 24.
5
The Effect of Liver and Kidney Disease on the Pharmacokinetics of Clozapine and Sildenafil: A Physiologically Based Pharmacokinetic Modeling.肝脏和肾脏疾病对氯氮平和西地那非药代动力学的影响:基于生理的药代动力学模型。
Drug Des Devel Ther. 2020 Apr 14;14:1469-1479. doi: 10.2147/DDDT.S246229. eCollection 2020.
6
Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.基于生理的药代动力学模型在预测严重肾功能损害人群米拉贝隆血浆浓度中的应用。
Biopharm Drug Dispos. 2019 May;40(5-6):176-187. doi: 10.1002/bdd.2181. Epub 2019 May 27.
7
Comparison of intravenous ibuprofen pharmacokinetics between Caucasian and Chinese populations using physiologically based pharmacokinetics modeling and simulation.应用基于生理的药代动力学模型和模拟技术比较白种人和中国人静脉用布洛芬的药代动力学。
Eur J Pharm Sci. 2023 Dec 1;191:106587. doi: 10.1016/j.ejps.2023.106587. Epub 2023 Sep 20.
8
Application of Physiologically Based Pharmacokinetic Model to Delineate the Impact of Aging and Renal Impairment on Ceftazidime Clearance.基于生理的药代动力学模型在描述衰老和肾功能损害对头孢他啶清除率影响中的应用。
Antibiotics (Basel). 2024 Sep 9;13(9):862. doi: 10.3390/antibiotics13090862.
9
Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling.使用基于生理的药代动力学模型对二肽基肽酶-IV抑制剂替格列汀进行人体药代动力学分析。
Biopharm Drug Dispos. 2015 Apr;36(3):148-62. doi: 10.1002/bdd.1928. Epub 2015 Jan 28.
10
In silico evaluation of gadofosveset pharmacokinetics in different population groups using the Simcyp® simulator platform.使用Simcyp®模拟器平台对不同人群组中钆弗塞特的药代动力学进行计算机模拟评估。
In Silico Pharmacol. 2014 Dec;2(1):2. doi: 10.1186/s40203-014-0002-x. Epub 2014 Jun 12.

引用本文的文献

1
Lamivudine and Emtricitabine Dosing Proposal for Children with HIV and Chronic Kidney Disease, Supported by Physiologically Based Pharmacokinetic Modelling.基于生理药代动力学模型支持的针对感染艾滋病毒和患有慢性肾病儿童的拉米夫定和恩曲他滨给药方案
Pharmaceutics. 2023 May 6;15(5):1424. doi: 10.3390/pharmaceutics15051424.
2
Evaluation of Renal Impairment Influence on Metabolic Drug Clearance using a Modelling Approach.运用建模方法评估肾功能损害对药物代谢清除率的影响。
Clin Pharmacokinet. 2023 Feb;62(2):307-319. doi: 10.1007/s40262-022-01205-3. Epub 2023 Jan 11.
3
Physiologically based pharmacokinetic modelling and simulation to predict the plasma concentration profile of schaftoside after oral administration of total flavonoids of .

本文引用的文献

1
Ontogeny of plasma proteins, albumin and binding of diazepam, cyclosporine, and deltamethrin.血浆蛋白、白蛋白以及地西泮、环孢素和溴氰菊酯结合的个体发生。
Pediatr Res. 2016 Mar;79(3):409-15. doi: 10.1038/pr.2015.237. Epub 2015 Nov 16.
2
Bayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant Populations.基于贝叶斯群体生理药代动力学(PBPK)方法对临床相关群体个体间变异性进行生理现实特征描述
PLoS One. 2015 Oct 2;10(10):e0139423. doi: 10.1371/journal.pone.0139423. eCollection 2015.
3
Consequences of renal failure on non-renal clearance of drugs.
基于生理的药代动力学建模与模拟,以预测口服……总黄酮后schaftoside的血浆浓度曲线 。 你提供的原文似乎不完整,“of”后面缺少具体内容。
Front Pharmacol. 2022 Dec 14;13:1073535. doi: 10.3389/fphar.2022.1073535. eCollection 2022.
肾衰竭对药物非肾清除的影响。
Clin Pharmacokinet. 2014 Jun;53(6):521-32. doi: 10.1007/s40262-014-0146-1.
4
A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam.基于 PBPK 模型支持儿科研发的工作流程示例:以劳拉西泮为例的案例研究。
AAPS J. 2013 Apr;15(2):455-64. doi: 10.1208/s12248-013-9451-0. Epub 2013 Jan 24.
5
Pharmacokinetics of cyclosporin--a microemulsion in children with idiopathic nephrotic syndrome.环孢素的药代动力学——一种微乳剂在特发性肾病综合征儿童中的应用。
Clinics (Sao Paulo). 2012 Oct;67(10):1197-202. doi: 10.6061/clinics/2012(10)12.
6
Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions.生理药代动力学建模和模拟在解决临床药理学监管问题方面的最佳实践。
Clin Pharmacol Ther. 2012 Jul;92(1):17-20. doi: 10.1038/clpt.2012.68.
7
Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development.东亚人和欧洲人在药代动力学/药效学相关基因的主要功能多态性方面的人群差异:对新药开发临床试验的影响。
Drug Metab Pharmacokinet. 2012;27(1):9-54. doi: 10.2133/dmpk.dmpk-11-rv-111. Epub 2011 Nov 29.
8
Cyclosporine Monitoring and Pharmacokinetics in Pediatrie Liver Transplant Patients.小儿肝移植患者中环孢素的监测与药代动力学
Transplant Proc. 1985 Feb;17(1):1172-1175.
9
Significance of protein binding in pharmacokinetics and pharmacodynamics.蛋白质结合在药代动力学和药效学中的意义。
J Pharm Sci. 2010 Mar;99(3):1107-22. doi: 10.1002/jps.21916.
10
Altered nonrenal drug clearance in ESRD.终末期肾病患者非肾性药物清除率的改变。
Curr Opin Nephrol Hypertens. 2008 Nov;17(6):555-9. doi: 10.1097/MNH.0b013e3283136732.